PMID: 16512692Mar 4, 2006Paper

Pulmonary arterial hypertension : a comprehensive review of pharmacological treatment

Treatments in Respiratory Medicine
Erika Berman Rosenzweig, Robyn J Barst

Abstract

The treatment of pediatric pulmonary arterial hypertension (PAH) is challenging due to the serious nature of the disease, its rapid progression, and the limited treatment options available. While oral calcium channel antagonists and continuous intravenous epoprostenol have been used successfully for over a decade, novel treatment options - including prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors - may change the course of this disease for many children in the future.Prostacyclin analogs offer the benefit over continuous intravenous epoprostenol of an alternative delivery system. However, the efficacy of these medications compared with intravenous epoprostenol and the risk/benefits of each analog need to be weighed in future trials, which need to include larger numbers of pediatric patients to optimize therapy and outcome for individual children with PAH.For patients who do not have an acute response to vasodilator testing or have failed treatment with oral calcium channel antagonists, endothelin receptor antagonists may offer a viable treatment option. Furthermore, in the future, the addition of endothelin receptor antagonists to long-term therapy with calcium channel antagonists or to...Continue Reading

References

Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Mar 15, 1991·Annals of Internal Medicine·D J StewartD Langleben
Jul 1, 1986·The Journal of Clinical Investigation·F Murad
Dec 1, 1986·British Journal of Pharmacology·T AkibaN Toda
Jan 1, 1974·Advances in Cardiology·C A Wagenvoort, N Wagenvoort
Jun 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·K SchrörR Ohlendorf
Oct 1, 1984·Clinical Pharmacology and Therapeutics·S KaukinenH Vapaatalo
Apr 17, 1995·Biochemical and Biophysical Research Communications·S OzakiM Yano
Jan 19, 1995·The American Journal of Cardiology·J H PattersonR A McKinnis
Mar 30, 1994·Biochemical and Biophysical Research Communications·T FukurodaM Nishikibe
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Apr 8, 1998·Circulation·A M Gotto
Mar 9, 1999·Circulation·R J BarstA P Fishman
Apr 20, 1999·Pulmonary Pharmacology & Therapeutics·D C UnderwoodD W Hay
Jun 3, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·S RouxM Clozel
Oct 16, 1999·Journal of the American College of Cardiology·N NagayaT Kunieda
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
May 3, 2002·Journal of the American College of Cardiology·Nazzareno GalièUNKNOWN Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group
Aug 2, 2002·The New England Journal of Medicine·Horst OlschewskiUNKNOWN Aerosolized Iloprost Randomized Study Group

❮ Previous
Next ❯

Citations

Mar 2, 2011·The European Respiratory Journal·R J BarstD D Ivy
Aug 22, 2007·PPAR Research·Rachel E NisbetC Michael Hart
May 26, 2016·Respiratory Medicine Case Reports·Kelsey Guerreso, Edward Alexander Conner
Apr 12, 2011·The American Journal of the Medical Sciences·Angel López-CandalesBeth Gulyasy
Nov 26, 2013·Clinics in Chest Medicine·Vallerie V McLaughlin, Harold I Palevsky
Nov 26, 2013·Clinics in Chest Medicine·Maor SaulerTerence K Trow
Jan 5, 2012·Chest·Laura C PriceMarc Humbert
Jun 13, 2015·Chest·Harrison W FarberRaymond L Benza
Aug 4, 2012·The American Journal of Cardiology·Shelley ShapiroDonald E Kohan
Jul 4, 2012·Heart Failure Clinics·Richa Agarwal, Mardi Gomberg-Maitland
Jul 4, 2012·Heart Failure Clinics·Robert P Frantz, Michael D McGoon
Feb 24, 2011·Revista española de medicina nuclear·V M Pachón GarrudoR Vázquez Albertino
Jul 9, 2010·The Veterinary Clinics of North America. Small Animal Practice·Heidi B Kellihan, Rebecca L Stepien
Dec 22, 2009·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Jagdish HiremathUNKNOWN TRUST Study Group
Dec 1, 2009·Progress in Pediatric Cardiology·D D IvyE B Rosenzweig
Apr 14, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Pinar Yildiz
Jan 10, 2009·Thrombosis Research·Maciej KostrubiecPiotr Pruszczyk
Jun 17, 2008·Clinical Therapeutics·Judy W M Cheng
Apr 28, 2007·Seminars in Pediatric Surgery·Doug Miniati
Jan 15, 2008·Journal of the American College of Cardiology·D Dunbar IvySteven H Abman
Dec 2, 2009·Korean Circulation Journal·Seung-Kyung HwangMyung-Kul Yum
Sep 27, 2015·European Journal of Pharmacology·Ai-Ping WangYuan-Jian Li
Oct 30, 2016·European Journal of Pharmacology·Juan LiJianming Pei
Jun 7, 2016·Chest·Hossein-Ardeschir GhofraniJames R Klinger
Apr 2, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mariko Harada-ShibaKazunori Kataoka
Nov 20, 2016·Journal of Cellular and Molecular Medicine·Shirley FavreGiuseppina Milano
Jun 14, 2008·Prenatal Diagnosis·Priscilla Chiu, Holly L Hedrick
Dec 26, 2009·Paediatric Drugs·Natalie J Carter, Gillian M Keating
Nov 3, 2020·Current Opinion in Cardiology·Dunbar Ivy, Benjamin S Frank
Apr 28, 2007·Seminars in Pediatric Surgery·Hadi Mohseni-Bod, Desmond Bohn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.